RxDoctor Payments Data

Lawrence Phillips, MD

Cardiovascular Disease · New York, NYNPI 1447420369

Payments from drug & device makers

$9,553in general payments, 2019–2025

Across 20 payments — averaging $477.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$5K
  • Eli Lilly$4K
  • Novartis$143
  • Johnson & Johnson$82
  • Amgen$26
  • Bayer$22
  • plus $19 from 1 others
$380,163in research payments, 2019–2025

Across 158 payments — averaging $2406.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novo Nordisk AS$344K
  • Eli Lilly$36K

What the payments were for

  • Speaking & faculty fees$4,80093%
  • Food & beverage$3667%

General payments by program year

19
20
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer6$4,873
Eli Lilly1$4,388
Novartis6$143
Johnson & Johnson4$82
Amgen1$26
Bayer1$22
Boehringer Ingelheim1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,553 in reported general payments places this provider in the 75th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$201,127
Medicare patients
1,797
Services billed
3,580

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban319$365,452
XareltoRivaroxaban39$50,958
EntrestoSacubitril/Valsartan43$42,696
JardianceEmpagliflozin31$40,110
Repatha SureclickEvolocumab29$29,098
MultaqDronedarone Hcl17$19,129
Repatha SyringeEvolocumab13$7,706
Praluent PenAlirocumab14$7,601
Rosuvastatin Calcium357$5,977
Ezetimibe159$5,357
Atorvastatin Calcium393$4,664
Metoprolol Succinate283$4,632
Losartan Potassium171$2,452
Amlodipine Besylate197$1,684
Diltiazem 24hr Er (Cd)Diltiazem Hcl35$1,100

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$4,873$365,452319 claims
Johnson & JohnsonXarelto$82$50,95839 claims
NovartisEntresto$143$42,69643 claims
Boehringer IngelheimJardiance$19$40,11031 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →